Semaglutide

Mechanism

Semaglutide mimics a natural gut hormone called GLP-1 that is released after eating, which tells your brain you are full and signals your pancreas to manage blood sugar more effectively. It slows stomach emptying, reduces appetite, and helps the body use insulin more efficiently, leading to significant weight loss and improved metabolic health. It is one of the most clinically validated peptides available, with FDA approval for both type 2 diabetes and chronic weight management.

Effects

GLYCEMIC [Tier 1 – FDA-Approved]: Semaglutide is a 31-amino-acid GLP-1 receptor agonist with 94% homology to native GLP-1, engineered with Aib8 substitution (DPP-4 resistance) and C18 fatty diacid chain (albumin binding, half-life ~7 days). The most extensively studied GLP-1 agonist in history. SUSTAIN program: HbA1c reductions 1.5-1.8% in type 2 diabetes. Available as injection (Ozempic for T2D, Wegovy for obesity) and oral (Rybelsus for T2D). WEIGHT LOSS [Tier 1 – FDA-Approved]: STEP trial program established semaglutide 2.4 mg weekly as a transformative obesity treatment. STEP 1 (Wilding et al., 2021, NEJM): 14.9% mean body weight loss at 68 weeks (vs 2.4% placebo). ~32% achieved ≥20% weight loss. This was the trial that catalyzed the global GLP-1 revolution. Weight loss results consistent across populations, genders, and comorbidities. CARDIOVASCULAR [Tier 1 – FDA-Approved / Landmark]: SUSTAIN-6 (n=3297): 26% MACE reduction (HR 0.74). SELECT trial (n=17,604): Semaglutide 2.4 mg reduced MACE by 20% in overweight/obese patients WITHOUT diabetes — first obesity drug to show cardiovascular benefit independent of diabetes. This expanded the cardiovascular indication beyond diabetic populations. RENAL [Tier 1 – Human Clinical]: FLOW trial (2024): Semaglutide reduced risk of kidney disease progression by 24% in type 2 diabetes with chronic kidney disease. First GLP-1 RA to demonstrate renal outcome benefit in a dedicated kidney trial. LIVER [Tier 1 – Human Clinical]: Significant liver fat reduction (30-40%) demonstrated across multiple studies. Ongoing Phase III trials in NASH. Semaglutide may become one of the first approved NASH treatments. NEUROLOGICAL [Tier 2 – Limited Human]: Ongoing trials in Alzheimer disease. GLP-1R activation in the brain has neuroprotective effects. Weight loss itself improves cognitive function. Early results promising but not definitive. GASTROINTESTINAL [Tier 1 – Human Clinical]: Nausea (20-44%), vomiting (5-24%), diarrhea (8-20%), constipation (5-24%). Predominantly during dose titration. Most resolve within 4-8 weeks at each dose level. Gastric emptying significantly delayed.

Practitioner Guide

CLINICAL POSITIONING: Semaglutide is the most important metabolic peptide of the 2020s. It is the benchmark against which all other GLP-1 agonists and weight loss agents are measured. Every practitioner in metabolic medicine, endocrinology, or peptide optimization must have deep fluency with semaglutide. DOSING: • Ozempic (T2D): 0.25 mg weekly x 4 weeks → 0.5 mg weekly x 4 weeks → 1.0 mg weekly (maintenance). Max 2.0 mg weekly. • Wegovy (obesity): 0.25 mg weekly x 4 weeks → 0.5 mg weekly x 4 weeks → 1.0 mg weekly x 4 weeks → 1.7 mg weekly x 4 weeks → 2.4 mg weekly (maintenance). • Rybelsus (oral, T2D): 3 mg daily x 30 days → 7 mg daily → 14 mg daily. MUST take on empty stomach with ≤4 oz water, 30 min before food/drinks/other medications. TITRATION STRATEGIES — THE ART OF SEMAGLUTIDE: • The standard titration schedule is MINIMUM. Many patients benefit from SLOWER titration. • "Extended titration": Stay at 0.25 mg for 8 weeks instead of 4. Then 0.5 mg for 8 weeks. Dramatically reduces nausea. • "Half-step" titration: Some practitioners use 0.375 mg (between 0.25 and 0.5), then 0.75 mg, etc. This requires compounded semaglutide or careful pen dosing. • The goal is NOT to reach 2.4 mg ASAP. The goal is to find the MINIMUM EFFECTIVE DOSE for that patient. Some patients achieve excellent results at 1.0 mg. Pushing to 2.4 mg for everyone is over-treatment. • "Dose to response": Once patient is losing 1-2 lbs/week consistently, they may not need further escalation regardless of nominal target dose. NAUSEA MANAGEMENT — COMPREHENSIVE: • Prevention: Slow titration is #1. Smaller meals. Avoid greasy, fried, heavy foods (hard to digest with delayed gastric emptying). Stop eating when satisfied, NOT full — the semaglutide brain knows before the stomach does. • First-line: Ginger (capsules 250 mg with meals, or ginger tea). Peppermint tea. Small sips of water throughout day. • Second-line: Ondansetron (Zofran) 4-8 mg PRN (watch for constipation — already a semaglutide side effect). • Third-line: If nausea is intolerable, REDUCE DOSE. Drop back to previously tolerated dose for 4-8 weeks, then re-attempt escalation. • Timeline: Nausea typically peaks at each dose increase, is worst days 2-4 post-injection, and resolves within 1-2 weeks. MUSCLE PRESERVATION — THE CRITICAL PROTOCOL: Weight loss of 15%+ means substantial lean mass loss risk. This is the #1 concern with aggressive semaglutide therapy. • PROTEIN: 1.2-1.6 g/kg GOAL body weight per day. This is non-negotiable. At reduced caloric intake, protein must be 30-40% of calories. Protein shakes may be necessary — appetite suppression makes it hard to eat enough protein from food alone. • RESISTANCE TRAINING: 2-4x/week. Progressive overload (increase weight/reps over time). Full body or upper/lower split. This is the single most important intervention for lean mass preservation. • CREATINE: 5 g/day monohydrate. Supports muscle performance, hydration, and may attenuate lean mass loss. • LEUCINE: 2-3 g per meal (included in protein target, not additional). Maximizes muscle protein synthesis per meal. • HMB (Beta-Hydroxy Beta-Methylbutyrate): 3 g/day. Evidence for preventing muscle catabolism during caloric deficit. Optional but helpful for patients >50 or those losing rapidly. • DEXA MONITORING: Every 3-6 months if available. Track lean mass vs fat mass trends. If lean mass dropping disproportionately (>35% of weight lost is lean), intervene aggressively. MANAGING "GLP-1 FACE": • Caused by rapid facial subcutaneous fat loss + possible collagen changes from caloric restriction. • Prevention: Slow, steady weight loss (1-2 lbs/week, not 3-4). Adequate protein. Hydration. • Treatment: Dermal fillers (hyaluronic acid — Juvederm, Restylane) for volume restoration. Collagen-stimulating treatments (Sculptra, microneedling). Red light therapy (some evidence for skin quality). • Nutrition: Collagen peptides 10-15 g/day (Type I and III). Vitamin C 500-1000 mg/day (cofactor for collagen synthesis). Adequate dietary fat (do not go ultra-low-fat — skin needs fatty acids). • Counsel patients BEFORE starting: "Your face may look thinner. This is a known effect of significant weight loss, not specific to this medication." COMPOUNDING vs BRAND: • Semaglutide has been on the FDA shortage list intermittently since 2022, allowing 503B compounding pharmacies to produce compounded semaglutide. • Brand Ozempic/Wegovy: FDA-approved, insurance may cover, quality guaranteed, ~$800-1400/month cash price. • Compounded semaglutide: Typically $150-400/month. Available as semaglutide base or semaglutide sodium salt. Quality varies dramatically by pharmacy. • KEY CONCERN: Compounded semaglutide is NOT bioequivalent to brand in all cases. Semaglutide sodium salt (most common compounded form) has different pharmacokinetics than semaglutide acetate (brand). Some patients report different efficacy/side effect profiles. • BEST PRACTICE: Use reputable 503B outsourcing facilities with third-party testing. Verify Certificate of Analysis (COA). If patient can afford brand and insurance covers it, brand is preferred. • FDA has signaled intent to restrict semaglutide compounding once shortage resolves — practitioners and patients should be prepared for supply disruption. TRANSITIONING BETWEEN AGENTS: • Semaglutide → Tirzepatide: Stop semaglutide. Start tirzepatide 2.5 mg one week later. Titrate normally. Expect improved weight loss (tirzepatide generally produces 5-8% more weight loss than semaglutide at equivalent dosing). • Tirzepatide → Semaglutide: Unusual (downgrade), but happens if tirzepatide supply disrupted. Stop tirzepatide, start semaglutide 0.5-1.0 mg one week later (patient has GLP-1 conditioning from tirzepatide). Expect some weight regain as efficacy is typically lower. • Adding to existing protocol: Some practitioners add low-dose semaglutide to other peptide stacks for appetite/metabolic control. WHAT HAPPENS WHEN PATIENTS STOP: • STEP 1 extension (Wilding et al., 2022, Diabetes Obes Metab): After stopping semaglutide, patients regained approximately 2/3 of lost weight within 1 year. Cardiometabolic improvements also reversed. • Appetite returns within 2-4 weeks as semaglutide clears (long half-life = gradual return). • This is NOT a "failure" of the drug — it is the natural consequence of removing an appetite-suppressing medication. Obesity is a chronic disease requiring chronic treatment (like hypertension). • MAINTENANCE STRATEGIES: - Continue semaglutide at maintenance dose long-term (preferred if affordable/tolerated). - Reduce to minimum effective dose (some patients maintain on 0.5-1.0 mg after losing weight on 2.4 mg). - Transition to lower-cost GLP-1 alternative for maintenance (liraglutide, compounded semaglutide at lower dose). - If stopping entirely: Intensive lifestyle support (dietitian, trainer, behavioral support). Set realistic expectation that some regain is likely. Establish weight "guardrails" — if patient regains >5%, re-initiate medication. LONG-TERM SUSTAINABILITY: • The evidence supports long-term use. SUSTAIN and STEP extension data show maintained efficacy over 2+ years. • Side effects generally improve over time (nausea resolves, GI tolerance develops). • Annual monitoring: HbA1c (if diabetic), lipid panel, comprehensive metabolic panel, body composition, thyroid function (precautionary — rodent C-cell tumor signal, not confirmed in humans at >7 years post-marketing). • Discuss with patients: This is likely a long-term or lifelong medication for chronic weight management, similar to statins for cholesterol or antihypertensives for blood pressure.

Dosing Protocols

Contraindications & Cautions

• hard stop — History of pancreatitis
  GLP-1 receptor agonists are associated with increased risk of pancreatitis. Patients with a history of pancreatitis are at substantially elevated risk of recurrence. Cases of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, have been reported.
  Action: Do not use. This is a contraindication per prescribing information. Refer to physician for alternative weight management or metabolic therapies.
• hard stop — Medullary thyroid carcinoma or MEN2 syndrome
  GLP-1 receptor agonists cause dose-dependent thyroid C-cell tumors in rodents. Patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) are at unacceptable risk.
  Action: Absolutely contraindicated. Do not use under any circumstances. This is a black box warning. Refer to oncologist/endocrinologist.
• hard stop — Pregnancy
  GLP-1 agonists have demonstrated embryo-fetal toxicity in animal studies. Weight loss during pregnancy offers no benefit and may cause fetal harm. Semaglutide should be discontinued at least 2 months before planned conception due to long half-life.
  Action: Discontinue immediately if pregnancy is detected. Do not initiate during pregnancy. Discontinue at least 2 months before planned conception.
• hard stop — Breastfeeding
  Insufficient data on excretion in human breast milk. Potential risk to nursing infant from weight-loss-inducing peptide exposure. Risk-benefit does not support use.
  Action: Do not use while breastfeeding. Consider alternative approaches to health goals during lactation.
• hard stop — Gastroparesis
  GLP-1 agonists significantly delay gastric emptying. In patients with pre-existing gastroparesis, this can cause severe nausea, vomiting, abdominal pain, and dangerous gastric retention. Risk of aspiration and bowel obstruction.
  Action: Do not use in patients with diagnosed gastroparesis or severe GI motility disorders. Refer to gastroenterologist for evaluation.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Developing endocrine, metabolic, and neurological systems may be adversely affected. Insufficient safety data in minors.
  Action: Do not provide peptide protocols to individuals under 18. Refer to pediatric endocrinologist if clinically appropriate.
• hard stop — Other GLP-1 receptor agonists
  Concurrent use of multiple GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide, liraglutide, etc.) causes additive or synergistic effects on gastric emptying, appetite suppression, and insulin secretion. Risk of severe GI events, pancreatitis, and hypoglycemia.
  Action: Never combine multiple GLP-1 agonists. Ensure washout of prior GLP-1 agonist before switching.
• requires physician — Insulin
  Concurrent use with insulin significantly increases risk of hypoglycemia. GLP-1 agonists potentiate insulin secretion and may cause dangerously low blood glucose when combined with exogenous insulin.
  Action: Do not initiate without physician supervision. Insulin dose reduction typically required. Frequent blood glucose monitoring mandatory.
• requires physician — Sulfonylureas
  Sulfonylureas stimulate insulin secretion independent of blood glucose. Combined with GLP-1 agonist glucose-dependent insulin secretion, severe hypoglycemia risk increases substantially.
  Action: Physician must evaluate sulfonylurea dose reduction before initiating. Blood glucose monitoring required. Educate on hypoglycemia signs and management.
• monitor — Metformin
  GLP-1 agonists slow gastric emptying, which may alter metformin absorption kinetics. Additive gastrointestinal side effects (nausea, diarrhea) are common. Hypoglycemia risk is low but present.
  Action: Monitor for increased GI side effects. No dose adjustment typically required. Ensure adequate hydration. Monitor blood glucose during titration.
• requires physician — History of eating disorders
  GLP-1 agonists cause significant appetite suppression and weight loss. In patients with history of anorexia nervosa, bulimia, or other eating disorders, these effects may trigger relapse or exacerbate disordered eating behaviors.
  Action: Requires physician evaluation and mental health screening before initiation. Ongoing monitoring by both prescriber and mental health professional recommended. Monitor weight, nutritional status, and psychological wellbeing.

Evidence

• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials

  Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ (2025) — Ann Intern Med — PMID: 39761578

  Retatrutide 12mg/week produced greatest weight loss: 22.1% at 48 weeks. Tirzepatide 15mg/week: 17.8% at 72 weeks. Semaglutide 2.4mg/week: 13.9% at 68 weeks. Liraglutide 3.0mg/day: 5.8% at 26 weeks. AEs predominantly gastrointestinal (nausea, vomiting, diarrhea), mostly mild-moderate. Serious AEs rare (0-10%). Retatrutide is most efficacious agent yet tested for obesity without diabetes.

  strong

• Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis

  de Paiva IHR, da Silva RS, Mendonca IP, de Souza JRB, Peixoto CA (2024) — J Neuroimmune Pharmacol — PMID: 39042202

  Weekly semaglutide (0.05 mg/kg IP) mitigated anxiety- and depression-like behaviors in T2D mice, enhanced cognition, protected synaptic plasticity, reduced hippocampal neuroinflammation, increased serotonin and GLP-1R neurons, and improved gut microbiota (Bacteroidetes/Blautia coccoides) while reducing intestinal permeability.

  moderate

• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)

  Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esber S, Inzucchi SE, Kosiborod MN, Lingvay I, Malanda B, McGuire DK, Michelsen MM, Plutzky J, Reas DL, Riddle MC, Rydén L, Schnell O, Standl E, Valensi P, Wise RA, Kalra S, Husain M (2023) — New England Journal of Medicine — PMID: 37952131

  Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% vs placebo (HR 0.80, 95% CI 0.72-0.90) in overweight/obese adults without diabetes over mean 39.8 months. First trial to demonstrate CV benefit of a weight-loss medication independent of diabetes. Mean weight loss -9.39% vs -0.88%.

  strong

• Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

  Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF (2021) — New England Journal of Medicine — PMID: 33567185

  Semaglutide 2.4 mg weekly produced mean body weight reduction of -14.9% vs -2.4% with placebo over 68 weeks in adults with BMI >= 30 (or >= 27 with comorbidities). 86.4% of semaglutide patients achieved >= 5% weight loss vs 31.5% with placebo. Common side effects were GI (nausea, diarrhea, vomiting), mostly mild-to-moderate and transient.

  strong

• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)

  Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T (2016) — New England Journal of Medicine — PMID: 27633186

  Subcutaneous semaglutide significantly reduced major adverse cardiovascular events (MACE) by 26% vs placebo (HR 0.74, 95% CI 0.58-0.95) in patients with T2D at high cardiovascular risk. Significant reductions in nonfatal stroke and nonfatal MI. HbA1c reduced by 0.7-1.0% more than placebo.

  strong

Stacks featuring this peptide

Research Summary

TIER 1 (Human Clinical Trials / FDA-Approved): • SUSTAIN Program (Phase III, T2D): SUSTAIN 1-10. HbA1c reductions 1.5-1.8%. Superior to sitagliptin, exenatide ER, dulaglutide, insulin glargine. SUSTAIN-6 (Marso et al., 2016, NEJM): 26% MACE reduction (HR 0.74, CI 0.58-0.95), n=3297. • STEP Program (Phase III, obesity): STEP 1 (Wilding et al., 2021, NEJM): 14.9% weight loss at 68 weeks, n=1961. STEP 2 (T2D + obesity): 9.6% weight loss. STEP 3 (with intensive behavioral therapy): 16.0%. STEP 4 (withdrawal): Weight regain after stopping. STEP 5 (2-year data): 15.2% maintained at 2 years. • SELECT (Lincoff et al., 2023, NEJM): Cardiovascular outcomes in obesity WITHOUT diabetes, n=17,604. 20% MACE reduction (HR 0.80, CI 0.72-0.90). Paradigm-shifting — first anti-obesity drug with cardiovascular benefit in non-diabetic population. • FLOW (Perkovic et al., 2024, NEJM): Renal outcomes in T2D + CKD, n=3533. 24% reduction in kidney disease progression. First GLP-1 RA renal outcome trial. • FDA approvals: Ozempic (T2D, 2017), Rybelsus (oral, T2D, 2019), Wegovy (obesity, 2021). Cardiovascular and renal indications added to labels. TIER 2 (Limited Human / Strong Preclinical): • NASH: Phase II data showing 30-40% liver fat reduction and histological NASH resolution in ~60% of patients. Phase III ongoing. • Alzheimer disease: Phase II/III trials ongoing (GLP-1R activation is neuroprotective in preclinical models). • Obstructive sleep apnea: Significant improvement in AHI (apnea-hypopnea index) in clinical studies. • Heart failure with preserved ejection fraction (HFpEF): STEP-HFpEF showed improved symptoms and exercise capacity. • Peripheral artery disease, polycystic kidney disease, addiction (alcohol/nicotine) — ongoing investigations. TIER 3 (Preclinical / Mechanistic): • Central GLP-1R activation: Hypothalamic appetite suppression, brainstem nausea/satiety signaling, reward center modulation (reduced food craving, potentially reduced addictive behaviors). • Anti-inflammatory: Reduces CRP, IL-6, TNF-α independent of weight loss. • Cardioprotective mechanisms: Reduced arterial inflammation, improved endothelial function, anti-atherosclerotic effects. • Rodent thyroid C-cell tumors (black box warning): Not confirmed in humans. >7 years of post-marketing data with no signal. Species-specific finding related to rodent GLP-1R expression on C-cells. EVIDENCE GAPS: 10+ year safety data still accumulating. Thyroid C-cell concern technically unresolved (very low probability but box warning remains). Optimal long-term dosing for weight maintenance (is 2.4 mg needed forever, or can patients step down?). Compounded semaglutide bioequivalence not formally studied. Effect on lean mass during weight loss needs better characterization with different protein/exercise interventions. Addiction/craving reduction mechanism not fully elucidated.